Preclinical development

New study results show that an experimental drug may prevent or slow vision loss in people with diabetes. The researchers at Wilmer Eye Institute, Johns Hopkins Medicine used mouse as well as human retinal organoids and eye cell lines in their investigations. Eye conditions that cause vision loss are common complications of diabetes, affecting nearly […]

PerkinElmer’s Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions company. Based on two words, ‘revolutionise’ (rev) and ‘vita’ (vit) meaning ‘life’ in Latin, Revvity will provide reagents, consumables, assays, instruments and software to customers from pharma and biotech, diagnostic labs, academia and government […]

Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted […]

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. While the global proteasome inhibitors market is expected to […]

BioIVT has acquired XenoTech, a provider of products and services for preclinical testing that specialises in ADME, DMPK and DDI testing of potential drug candidates.  Through the acquisition, BioIVT aims to expand the portfolio of research models and services that are available to its clients to support their R&D function.   “XenoTech has a well-established and excellent reputation […]

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. The company’s NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins and is being developed alongside GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2). Discovered by […]

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application Science Team Lead, Carterra.  The background  […]

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of preclinical development, hosted by DDW […]

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals discusses translational immuno-oncology assay development in […]

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human physiology due to species differences. […]